1. Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol. 2009; 27:3391–7.
2. Agaram NP, LaQuaglia MP, Alaggio R, et al. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol. 2019; 32:27–36.
3. Mosquera JM, Sboner A, Zhang L, et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013; 52:538–50.
4. Alaggio R, Zhang L, Sung YS, et al. A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol. 2016; 40:224–35.
5. Bahrami A, Gown AM, Baird GS, Hicks MJ, Folpe AL. Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall. Mod Pathol. 2008; 21:795–806.
6. Dehner CA, Broski SM, Meis JM, et al. Fusion-driven spindle cell rhabdomyosarcomas of bone and soft tissue: a clinicopathologic and molecular genetic study of 25 cases. Mod Pathol. 2023; 36:100271.
7. Le Loarer F, Cleven AH, Bouvier C, et al. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol. 2020; 33:404–19.
8. Radzikowska J, Kukwa W, Kukwa A, Czarnecka A, Krzeski A. Rhabdomyosarcoma of the head and neck in children. Contemp Oncol (Pozn). 2015; 19:98–107.
9. Kakkar A, Nambirajan A, Suri V, et al. Primary bone tumors of the skull: spectrum of 125 cases, with review of literature. J Neurol Surg B Skull Base. 2016; 77:319–25.
10. Pons Escoda A, Naval Baudin P, Mora P, et al. Imaging of skull vault tumors in adults. Insights Imaging. 2020; 11:23.
11. Flucke U, van Noesel MM, Siozopoulou V, et al. EWSR1: the most common rearranged gene in soft tissue lesions, which also occurs in different bone lesions: an updated review. Diagnostics (Basel). 2021; 11:1093.
12. WHO Classification of Tumours Editorial Board. WHO classification of tumours series, 5th ed. Vol. 3. Soft tissue and bone tumours. Lyon: International Agency for Research on Cancer;2020.
13. Bridge JA, Sumegi J, Druta M, et al. Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. Mod Pathol. 2019; 32:1593–604.
14. Wang GY, Thomas DG, Davis JL, et al. EWSR1-NFATC2 translocation-associated sarcoma clinicopathologic findings in a rare aggressive primary bone or soft tissue tumor. Am J Surg Pathol. 2019; 43:1112–22.
15. Kao YC, Sung YS, Zhang L, et al. EWSR1 fusions with CREB family transcription factors define a novel myxoid mesenchymal tumor with predilection for intracranial location. Am J Surg Pathol. 2017; 41:482–90.
16. Argani P, Harvey I, Nielsen GP, et al. EWSR1/FUS-CREB fusions define a distinctive malignant epithelioid neoplasm with predilection for mesothelial-lined cavities. Mod Pathol. 2020; 33:2233–43.
17. Watson S, Perrin V, Guillemot D, et al. Transcriptomic definition of molecular subgroups of small round cell sarcomas. J Pathol. 2018; 245:29–40.
18. Xu B, Suurmeijer AJ, Agaram NP, Zhang L, Antonescu CR. Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases. Histopathology. 2021; 79:347–57.
19. Chrisinger JSA, Wehrli B, Dickson BC, et al. Epithelioid and spindle cell rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusion: report of two cases. Virchows Arch. 2020; 477:725–32.
20. Schopf J, Uhrig S, Heilig CE, et al. Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions. Nat Commun. 2024; 15:51.
21. Michal M, Rubin BP, Agaimy A, et al. EWSR1-PATZ1-rearranged sarcoma: a report of nine cases of spindle and round cell neoplasms with predilection for thoracoabdominal soft tissues and frequent expression of neural and skeletal muscle markers. Mod Pathol. 2021; 34:770–85.
22. Brunac AC, Laprie A, Castex MP, et al. The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript. Pediatr Blood Cancer. 2020; 67:e28185.
23. Valerio E, Furtado Costa JL, Perez Fraile NM, et al. Intraosseous spindle cell/epithelioid rhabdomyosarcoma with TFCP2 rearrangement: a recent recognized subtype with partial response to alectinib. Int J Surg Pathol. 2023; 31:861–5.